Search
Now showing items 1-1 of 1
Developmental therapeutics consortium report on study design effects on trial outcomes in chronic myeloid leukaemia
(Wiley-Blackwell, 2012-05-01)
Eur J Clin Invest 2012; 42 (9): 10161026 Abstract Background Tyrosine kinase inhibitors (TKIs) have dramatically changed the treatment of chronic myeloid leukaemia (CML). Results from ongoing phase 3 trials with nilotinib ...